Abstract 2076P
Background
Hand foot syndrome is a distinct side effect associated with capecitabine. Celecoxib, a cyclooxygenase (COX 2) inhibitor is the only drug effective in randomized trials. However, its use in clinics has declined due to concerns regarding cardiac safety. In our trial, we describe the use of topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy.
Methods
The D torch trial randomized 264 patients with breast or GI cancers receiving capecitabine to apply either 1% topical diclofenac or placebo gel. Stratified permuted variable size block randomization was done using a computer-generated random numbers sequence. The primary objective was to compare the incidence of grade 2 or higher HFS in diclofenac and placebo arms. Secondary objectives were incidence of any grade HFS, capecitabine dose reduction due to HFS and adherence with application. Here, we report the results of the monotherapy subgroup.
Results
108 out of 264 patients received capecitabine monotherapy (56 in diclofenac arm and 52 in placebo arm). Baseline characteristics were well matched in both arms. The study group’s median age was 47 years (IQR 39.5-57.5). Majority were females (n=101, 93.5%). 67 patients (62%) had an ECOG performance status of 0-1, while the rest were PS 2. 95 patients (87.9%) had carcinoma breast and the remaining 13 patients had various gastrointestinal cancers. 63 patients (58.9%) and 41 patients (38.3%) had stage 3 and 4 disease respectively, whereas only 3 patients (2.8%) had stage 2 cancer. Overall, 12 patients developed grade 2 or higher hand foot syndrome, of which 2 were in diclofenac group and 10 were in placebo group (3.6% vs 19.2%, p=0.01). Any grade HFS was seen in 3 patients (5.4%) in diclofenac arm and 12 patients (23%) in placebo arm (p=0.008). Dose reductions of capecitabine were less frequent in the diclofenac arm compared to placebo (3.6% vs 19.2% p=0.01). Adherence to topical treatment was more in the diclofenac group compared to placebo (93.2% vs 82.2%, p=0.04).
Conclusions
Topical diclofenac gel significantly reduced the incidence of HFS in patients receiving capecitabine monotherapy. Topical diclofenac gel application led to less frequent dose reductions of capecitabine.
Clinical trial identification
CTRI/2021/01/030592 (Clinical Trials Registry of India).
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Alkem Laboratories.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06